| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. | Chief Financial Officer | Common Stock | 182,774 | $2,888,176 | $15.80 | 02 Apr 2025 | Direct |
| Arcutis Biotherapeutics, Inc. | Chief Financial Officer | Stock Option (right to buy) | 89,000 | 28 Feb 2025 | Direct | ||
| Frazier Lifesciences Acquisition Corp | Chief Financial Officer, Director | Class B Ordinary Shares | 0 | 22 Nov 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ARQT | Arcutis Biotherapeutics, Inc. | 02 Apr 2025 | 1 | -$151,698 | 4 | Chief Financial Officer | 03 Apr 2025, 16:21 |
| ARQT | Arcutis Biotherapeutics, Inc. | 28 Feb 2025 | 2 | $0 | 4 | Chief Financial Officer | 04 Mar 2025, 19:43 |
| ARQT | Arcutis Biotherapeutics, Inc. | 21 Sep 2024 | 2 | -$110,264 | 4 | Chief Financial Officer | 25 Sep 2024, 21:42 |
| ARQT | Arcutis Biotherapeutics, Inc. | 10 Apr 2024 | 2 | $0 | 4 | Chief Financial Officer | 11 Apr 2024, 20:32 |
| ARQT | Arcutis Biotherapeutics, Inc. | 10 Apr 2024 | 0 | $0 | 3 | Chief Financial Officer | 11 Apr 2024, 20:30 |
| /report/000089924322036936-topper-david-joseph-2022-11-22 | Frazier Lifesciences Acquisition Corp | 22 Nov 2022 | 1 | $0 | 4 | Chief Financial Officer, Director | 23 Nov 2022, 15:31 |